

Chapter 58

Linear Immunoglobulin A Dermatitis and Chronic Bullous Disease of Childhood

Caroline L. Rao & Russell P. Hall III

REFERENCES

1. Chorzelski TP et al: Immunofluorescence studies in the diagnosis of dermatitis herpetiformis and its differentiation from bullous pemphigoid. *J Invest Dermatol* **56**:373-380, 1971
2. Chorzelski TP, Jablonska S, Maciejowska E: Linear IgA bullous dermatosis of adults. *Clin Dermatol* **9**:383-392, 1991
3. Lawley TJ et al: Small intestinal biopsies and HLA types in dermatitis herpetiformis patients with granular and linear IgA skin deposits. *J Invest Dermatol* **74**:9-12, 1980
4. Leonard JN et al: Linear IgA disease in adults. *Br J Dermatol* **107**:301-316, 1982
5. Cohen DM et al: Linear IgA disease histopathologically and clinically masquerading as lichen planus. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **88**:196-201, 1999
6. Torchia D et al: Linear IgA disease presenting as prurigo nodularis. *Br J Dermatol* **155**:479-480, 2006.
7. Armstrong AW et al: Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. *J Cutan Pathol* **31**:393-397, 2004
8. Baden LA et al: Vancomycin-induced linear IgA bullous dermatosis. *Arch Dermatol* **124**:1186-1188, 1988
9. Carpenter S et al: Vancomycin-associated linear IgA dermatosis. *J Am Acad Dermatol* **26**:45-48, 1992
10. McWhirter JD et al: Linear IgA bullous dermatosis related to lithium carbonate. *Arch Dermatol* **123**:1120-1122, 1987
11. Waldman MA, Black DR, Callen JP: Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. *Clin Exp Dermatol* **29**:633-636, 2004
12. Billet SE et al: A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis. *Arch Dermatol* **144**: 774-778, 2008
13. Khan I et al: Drug-associated linear IgA disease mimicking toxic epidermal necrolysis. *Clin Exp Dermatol* **34**:715-717, 2009
14. Walsh SN, Kerchner K, Sanguexa OP: Localized palmar vancomycin-induced linear IgA bullous dermatosis occurring at supratherapeutic levels. *Arch Dermatol* **145**(5):603-604, 2009
15. Chorzelski TP, Jablonska S: IgA linear dermatosis of childhood (chronic bullous disease of childhood). *Br J Dermatol* **101**:535-542, 1979
16. Jablonska S et al: Linear IgA bullous dermatosis of childhood (Chronic bullous dermatosis of childhood). *Clin Dermatol* **9**:393-401, 1992
17. Dabrowski J et al: The ultrastructural localization of IgA deposits in chronic bullous disease of childhood (CBDC). *J Invest Dermatol* **72**:291-295, 1979
18. Zone JJ et al: Antigenic specificity of antibodies from patients with linear basement membrane deposition of IgA. *Dermatology* **189**(Suppl.):64-66, 1994
19. Wojnarowska F, Bhogal BS, Black MM: Chronic bullous disease of childhood and linear IgA disease of adults are IgA1-mediated diseases. *Br J Dermatol* **131**:201-204, 1994
20. Wojnarowska F et al: Chronic bullous disease of childhood, childhood cicatricial pemphigoid and linear IgA disease of adults: A comparative study demonstrating clinical and immunopathologic overlap. *J Am Acad Dermatol* **19**:792-805, 1988
21. Collier PM et al: Adult Linear IgA disease and chronic bullous disease of childhood: The association with human lymphocyte antigens Cw7, B8, DR3 and tumour necrosis factor influences disease expression. *Br J Dermatol* **141**:867-875, 1999
22. Sachs JA et al: A comparative serological and molecular study of linear IgA diseases and dermatitis herpetiformis. *Br J Dermatol* **118**:759-764, 1988
23. Venning VA et al: HLA type in bullous pemphigoid, cicatricial pemphigoid and linear IgA disease. *Clin Exp Dermatol* **14**:283-285, 1989

24. Flotte TJ et al: Immunopathologic studies of adult linear IgA bullous dermatosis. *Arch Path Lab Med* **109**:457-459, 1985
25. Hall RP, Lawley TJ: Characterization of circulating and cutaneous IgA immune complexes in patients with dermatitis herpetiformis. *J Immunol* **135**:1760-1765, 1985
26. Leonard JN et al: Evidence that the IgA in patients with linear IgA disease is qualitatively different from that of patients with dermatitis herpetiformis. *Br J Dermatol* **110**:315-321, 1983
27. Wojnarowska F et al: The localization of the target antigens and antibodies in linear IgA disease is heterogeneous and dependent on the methods used. *Br J Dermatol* **132**:750-757, 1995
28. Karpati S et al: Ultrastructural immunogold studies in two cases of linear IgA dermatosis. Are there two distinct types of this disease? *Br J Dermatol* **127**:112-118, 1992
29. Prost C et al: Diagnosis of adult linear IgA dermatosis by immunoelectron microscopy in 16 patients with linear IgA deposits. *J Invest Dermatol* **92**:39-45, 1989
30. Bhogal B et al: Linear IgA bullous dermatosis of adults and children: An immunoelectron microscopic study. *Br J Dermatol* **117**:289-296, 1987
31. Horiguchi Y et al: Linear IgA dermatosis: Report of an infantile case and analysis of 213 cases in Japan. *J Dermatol* **35**:737-743, 2008
32. Zone JJ et al: Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. *J Clin Invest* **85**:812-820, 1990
33. Ishiko A et al: 97-kDa linear IgA bullous dermatosis (LAD) antigen localizes to the lamina lucida of the epidermal basement membrane. *J Invest Dermatol* **106**:739-743, 1996
34. Zone JJ et al: The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. *J Invest Dermatol* **110**:207-210, 1998
35. Roh JY et al: The 120 kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis. *Br J Dermatol* **143**:104-111, 2000
36. Schumann H et al: The shed ectodomain of collagen XVII/BP 180 is targeted by autoantibodies in different blistering skin diseases. *Am J Pathol* **156**:685-695, 2000
37. Lin MS et al: Autoimmune responses in patients with linear IgA bullous dermatosis: Both autoantibodies and T lymphocytes recognize the NC16A domain of the BP 180 molecule. *Clin Immunol* **102**:310-319, 2002
38. Zillikens D et al: Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP180. *J Invest Dermatol* **113**:947-953, 1999
39. Wojnarowska F et al: Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults. *Br J Dermatol* **124**:157-162, 1991
40. Allen J, Wojnarowska F: Linear IgA disease: The IgA and IgG response to the epidermal antigens demonstrates that intermolecular epitope spreading is associated with IgA rather than IgG antibodies, and is more common in adults. *Br J Dermatol* **149**:977-985, 2003
41. Ishii N et al: IgA autoantibodies against the NC16a domain of BP180 but not 120-KDa LAD-1 detected in a patient with linear IgA disease. *Br J Dermatol* **158**:1151-1153, 2008
42. Peters MS, Rogers RS III. Clinical correlations of linear IgA deposition at the cutaneous basement membrane zone. *J Am Acad Dermatol* **20**:761-770, 1989
43. Perrett CM, Evans AV, Russell-Jones R: Tea Tree oil dermatitis associated with linear IgA disease. *Clin Exp Dermatol* **28**:167-170, 2003
44. Tran D, Kossard S, Shumack S: Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis. *Australas J Dermatol* **44**:284-286, 2003
45. Blockmans D et al: Linear IgA dermatosis: A new cause of fever of unknown origin. *Neth J Med* **47**:214-218, 1995
46. Leigh G, Marsden RA, Wojnarowska F: Linear IgA dermatosis with severe arthralgia. *Br J Dermatol* **119**:789-792, 1988
47. Kelly SE et al: A clinicopathological study of mucosal involvement in linear IgA disease. *Br J Dermatol* **119**:161-170, 1988
48. Leonard JN et al: The relationship between linear IgA disease and benign mucous membrane pemphigoid. *Br J Dermatol* **110**:307-314, 1984
49. Porter SR, Bain SE, Scully CM: Linear IgA disease manifesting as recalcitrant desquamative gingivitis. *Oral Surg* **74**:179-182, 1992
50. Sato K et al: Initial presentation and fatal complications of linear IgA bullous dermatosis in the larynx and pharynx. *J Laryngol Otol* **119**:314-318, 2005

51. deFranchis R et al: Small-bowel involvement in dermatitis herpetiformis and in linear IgA bullous dermatosis. *J Clin Gastroenterol* 5:429-436, 1983
52. Leonard JN et al: Experience with a gluten free diet in the treatment of linear IgA disease. *Acta Derm Venereol (Stockh)* 67:145-148, 1987
53. Rose C et al: Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease. *J Am Acad Dermatol* 41:957-961, 1999
54. Birnie, AJ, Perkins W. A case of linear IgA disease occurring in a patient with colonic Crohn's disease. *Br J Dermatol* 153:1050-1052, 2005
55. Paige DG et al: Linear IgA disease and ulcerative colitis. *Br J Dermatol* 136:779-782, 1997
56. Smitt JHS et al: Chronic bullous disease of childhood and a paecilomyces lung infection in chronic granulomatous disease. *Arch Dis Child* 77:150-152, 1997
57. Alberta-Wszolek L et al: Linear IgA bullous dermatosis following influenza vaccination. *Dermatol Online* 15:3, 2009
58. Kociyigit P, Akay BN, Karaosmanoglu N: Linear IgA bullous dermatosis induced by interferon-alpha 2a. *Clin Exp Dermatol* 34:123-124, 2009
59. Palmer RA et al: Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD 285. *Br J Dermatol* 145:816-820, 2001
60. Paul C et al: Drug-induced linear IgA disease: Target antigens are heterogeneous. *Br J Dermatol* 136:406-411, 1997
61. Joshi S, Scott G, Looney RJ: A successful challenge in a patient with vancomycin-induced linear IgA dermatosis. *Ann Allergy Asthma Immunol* 93:101-103, 2004
62. Godfrey K, Wojnarowska F, Leonard J: Linear IgA disease of adults: Association with lymphoproliferative malignancy and possible role of other triggering factors. *Br J Dermatol* 123:447-452, 1990
63. McEvoy MT, Connolly SM: Linear IgA dermatosis: Association with malignancy. *J Am Acad Dermatol* 22:59-63, 1990
64. Blenkinsopp WK et al: Histology of linear IgA disease, dermatitis herpetiformis and bullous pemphigoid. *Am J Dermatopathol* 5:547-554, 1983
65. Smith SB et al: Linear IgA bullous dermatosis v dermatitis herpetiformis: Quantitative measurements of dermoepidermal alterations. *Arch Dermatol* 120:324-328, 1984
66. Talhari C et al: Ocular linear IgA disease resulting in blindness. *Arch Dermatol* 142:766-767, 2006
67. Talhari C et al: Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent. *Clin Exp Dermatol* 30:297-298, 2005
68. Peterson JD, Chan LS: Linear IgA bullous dermatosis responsive to trimethoprim-sulfamethoxazole. *Clin Exp Dermatol* 32:756-758, 2007
69. Farley-Li J, Mancini AJ: Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. *Arch Dermatol* 139:1121-1124, 2003
70. Goebeler M et al: Successful treatment of linear IgA disease with salazosupphapyridine and intravenous immunoglobulins. *Br J Dermatol* 149:912-914, 2003
71. Kroiss MM, Vogt M, Landthaler WS: High-dose intravenous immune globulin is also effective in linear IgA disease. *Br J Dermatol* 142:582, 2000
72. Dauendorffer JN, Mahé E, Saiag P.: Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis. *J Eur Acad Dermatol Venereol* 22(3):364-365, 2008
73. Cooper SM, Powell J, Wojnarowska F: Linear IgA disease: Successful treatment with erythromycin. *Clin Exp Dermatol* 27:677-679, 2002
74. Siegfried EC, Sirawan S: Chronic bullous disease of childhood: Successful treatment with dicloxacillin. *J Am Acad Dermatol* 39:797-800, 1998
75. Alajlan A et al: Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin. *J Am Acad Dermatol* 54:652-656, 2006

